

CONTINUING REVIEW APPROVAL
CR00168066

DATE: 25 Nov 2019

TO: Erin Bengelink

PROTOCOL: National Institute of Neurological Disorders and Stroke, NIH - BOOST3, Brain Oxygen Optimization in Severe Traumatic Brain Injury - Phase 3 (BOOST-3): A multicenter, randomized, blinded-endpoint, comparative effectiveness study of goal-directed critical care based upon monitoring of brain tissue oxygen and intracranial pressure versus monitoring of intracranial pressure alone in patients with severe traumatic brain injury. (Pro00030585)

CONTINUING REVIEW APPROVAL DATE: 22 Nov 2019

EXPIRATION DATE: 22 Nov 2020

Thank you for providing the information required for Advarra IRB to conduct continuing review of the protocol.

In addition to the information you provided, the IRB reviewed the current protocol referenced above, the Consent Template(s) for the study, and other supporting information.

The IRB approved continuation of the above referenced protocol. The IRB determined changes to the Consent Template(s) were not necessary.

Please Note: Each Principal Investigator will receive a separate IRB Approval notice allowing them to continue the study.

If the study is expected to last beyond the approval period, you must request and receive re-approval prior to the expiration date noted above. A report to the Board on the status of this study is due prior to the expiration date or at the time the study closes, whichever is earlier. It is recommended that you submit status reports at least 4 weeks prior to your expiration date to avoid any additional fees or lapses in approval.

The IRB determined that the pediatric risk determination for this study has not changed from the original review of this protocol.

Approved investigators and sites are required to submit to Advarra for review, and await a response prior to implementing, any amendments or changes in: the protocol; advertisements or recruitment materials ("study-related materials"); investigators; or sites (primary and additional).

Page 1 of 2

Approved investigators and sites are required to notify Advarra of the following reportable events, including, but not limited to: unanticipated problems involving risks to subjects or others; unanticipated adverse device effects; protocol violations that may affect the subjects' rights, safety, or well-being and/or the completeness, accuracy and reliability of the study data; subject death; suspension of enrollment; or termination of the study.

Please review the IRB Handbook located in the "Reference Materials" section of Advarra CIRBI™ Platform (www.cirbi.net). A copy of the most recent IRB roster is also available.

We look forward to continuing to work with you on this project.